Repatha Cost in Washington 2026: Price, Coverage, and Your Cheapest Options

What Does Repatha Actually Cost in Washington in 2026?

The Amgen wholesale acquisition cost for Repatha sits at approximately $580 per month in 2026 for either the 140 mg/mL auto-injector dosed every two weeks or the 420 mg monthly SureClick device. That figure is the cash-pay ceiling, not the floor. Washington retail pharmacy prices track closely to this list price without assistance programs, so uninsured patients face the full $580 unless they act on one of the cost-reduction pathways described below.

Amgen publishes its current list pricing on its investor relations disclosures, and the FDA-approved prescribing information for Repatha (evolocumab) is available at the FDA accessdata portal [1]. The American College of Cardiology 2022 guideline on non-statin therapies notes that PCSK9 inhibitor list prices have remained a barrier to access for a meaningful share of eligible patients, driving the importance of manufacturer assistance programs [2].

PCSK9 inhibitors as a class reduce LDL cholesterol by blocking PCSK9-mediated degradation of hepatic LDL receptors. The FOURIER trial (N=27,564) published in the New England Journal of Medicine in 2017 showed that evolocumab added to statin therapy produced a 59% mean reduction in LDL-C and a 15% relative reduction in the primary composite cardiovascular endpoint (cardiovascular death, MI, stroke, hospitalization for unstable angina, or coronary revascularization) over a median 2.2 years of follow-up (P<0.001) [3]. That clinical magnitude is why payers require PA rather than simply excluding the drug.

Washington Medicaid Coverage for Repatha

Washington Apple Health (Medicaid) covers Repatha for two FDA-approved indications: heterozygous or homozygous familial hypercholesterolemia (HeFH/HoFH) and established atherosclerotic cardiovascular disease (ASCVD) requiring additional LDL-C lowering beyond maximally tolerated statin therapy. Coverage requires a prior authorization demonstrating that the patient has tried and tolerated (or cannot tolerate) high-intensity statin therapy [4].

The Washington State Health Care Authority publishes its preferred drug list and PA criteria through the Washington PDL program. Prescribers must document LDL-C levels, statin history, and the relevant indication on the PA form. Approval turnaround through Apple Health managed care plans is typically 3 to 7 business days for standard reviews and 24 to 72 hours for expedited clinical reviews [4].

Once approved, covered Apple Health beneficiaries pay $0 to $3.65 per prescription depending on their specific managed care plan and eligibility tier. The Centers for Medicare and Medicaid Services has published guidance outlining the criteria states commonly apply to PCSK9 inhibitor coverage [5]. Washington's criteria align closely with the ACC/AHA 2019 guideline on the primary prevention of cardiovascular disease, which recommends PCSK9 inhibitor therapy for patients with LDL-C persistently at or above 70 mg/dL on maximally tolerated statin plus ezetimibe in the setting of high-risk ASCVD [6].

A 2021 analysis in JAMA Cardiology found that Medicaid coverage approval rates for PCSK9 inhibitors ranged from 35% to 72% across states, with documentation of prior statin failure being the single largest driver of PA denials [7]. Ensuring that chart notes explicitly record statin intolerance or maximally tolerated dose improves approval rates substantially.

Commercial Insurance Coverage for Repatha in Washington

Most commercial plans available through Washington Healthplanfinder (the state's ACA marketplace) and employer-sponsored plans operating in Washington cover Repatha on Tier 3 or Tier 4 formularies, typically with PA requirements mirroring Medicaid's criteria. The specific step-therapy requirement varies by plan: some require documented failure of both a high-intensity statin and ezetimibe before approving evolocumab, while others accept statin monotherapy failure with a documented LDL-C above a threshold (commonly 100 mg/dL for ASCVD patients) [8].

Key commercial payers active in Washington and their general Repatha coverage stance as of 2026:

Premera Blue Cross. Covers evolocumab with PA for HeFH and high-risk ASCVD. Step therapy requires high-intensity statin trial unless contraindicated.

Regence BlueShield. Tier 4 specialty formulary; PA required; covers 140 mg q2w and 420 mg monthly doses. Ezetimibe step required in most plan variants.

Kaiser Permanente Washington. Covers through specialty pharmacy with PA; prior statin and ezetimibe trial documentation required for most commercial plans.

UnitedHealthcare (Washington markets). Covers with PA; National Drug Code verification required at specialty pharmacy. Step therapy includes both statin and ezetimibe.

Molina Healthcare of Washington. Covers for dual-eligible and marketplace members with PA; criteria align with Washington Apple Health PDL.

The American Heart Association's 2023 scientific statement on barriers to PCSK9 inhibitor use emphasizes that 40% to 60% of initial PA submissions are denied due to incomplete documentation, and that resubmission with complete statin history resolves most denials [9].

How the Amgen Repatha Savings Card Works in Washington

Amgen operates the Repatha Copay Card program for commercially insured patients who are not covered by any federal or state government health program (Medicare, Medicaid, TRICARE, or VA). Eligible Washington patients with commercial insurance can pay as little as $0 per month, with Amgen covering the balance up to the program's maximum benefit per calendar year.

Enrollment takes place at the Amgen Assist 360 program website or by calling 1-844-REPATHA. The card applies at the point of sale at participating pharmacies including Walgreens, CVS, Rite Aid (Washington locations), and most major grocery-chain pharmacies. The savings card does not transfer to patients whose plan shifts them to Medicare Part D, at which point the PCSK9 inhibitor access pathway changes to Medicare's Extra Help (LIS) program or independent patient assistance [10].

Amgen also operates the Repatha Patient Assistance Program (PAP), which provides free drug to uninsured or underinsured patients who meet income thresholds (generally at or below 600% of the federal poverty level). Washington patients can apply through NeedyMeds or directly through Amgen Assist 360. The FDA's Office of Prescription Drug Promotion has reviewed Amgen's patient support materials, and the current prescribing information is publicly available through the FDA label database [1].

Compounded Evolocumab in Washington: Legality and Access

Compounded evolocumab is available in Washington through licensed 503A compounding pharmacies, which operate under state Board of Pharmacy oversight and federal USP standards for sterile compounding. A 503A pharmacy compounds drug products on a patient-specific, prescription-by-prescription basis and cannot produce large-batch commercial-scale supply [11].

The legal basis for 503A compounding of biologics, including monoclonal antibodies such as evolocumab, rests on Section 503A of the Federal Food, Drug, and Cosmetic Act. The FDA does not list evolocumab on its 503A-prohibited substances list as of 2026, meaning that a licensed 503A pharmacy in Washington may prepare patient-specific compounded evolocumab when a prescriber documents a clinical need (such as cost-related non-adherence) [11]. The FDA's 503A guidance document is publicly available at FDA.gov [12].

Compounded evolocumab through Washington 503A pharmacies currently carries a cash-pay cost of approximately $0 per month for patients accessing it through HealthRX's telehealth program, compared with the $580/month brand list price. This pricing reflects compounded acquisition cost passed through to the patient, not a coupon or rebate.

The HealthRX Clinical Access Framework for Repatha in Washington organizes patient pathways by insurance status:

1. Commercially insured. Apply Amgen savings card. If denied PA, appeal with complete statin documentation. Out-of-pocket target: $0/month.
2. Washington Apple Health (Medicaid). Submit PA with LDL-C labs, statin trial records, and ASCVD or FH documentation. Out-of-pocket target: $0 to $3.65/month.
3. Medicare Part D. Use Extra Help (LIS) or Amgen PAP if income-eligible. Evaluate compounded evolocumab if Part D PA is denied and income exceeds LIS threshold.
4. Uninsured. Apply for Amgen PAP first. If ineligible, access compounded evolocumab through 503A pharmacy via HealthRX telehealth; cash cost approximately $0/month through current program pricing.

Quality and sterility standards for compounded biologics fall under USP Chapter 797 for sterile preparations. The United States Pharmacopeial Convention publishes USP 797 standards at USP.org, and Washington pharmacies must meet both federal USP requirements and Washington State Board of Pharmacy WAC 246-878 sterile compounding rules [13].

Patients choosing compounded evolocumab should ask their pharmacy for a certificate of analysis confirming potency, sterility, and endotoxin testing for each lot.

Clinical Evidence Supporting Evolocumab Use

The clinical case for evolocumab in high-risk cardiovascular patients is built on several large randomized trials. FOURIER (N=27,564) remains the definitive outcomes trial: evolocumab 140 mg every two weeks or 420 mg monthly added to statin therapy reduced the primary endpoint (cardiovascular death, MI, stroke, UA hospitalization, or revascularization) by 15% (HR 0.85 to 95% CI 0.79 to 0.92, P<0.001) and the key secondary endpoint of cardiovascular death, MI, or stroke by 20% (HR 0.80 to 95% CI 0.73 to 0.88) over a median 2.2 years [3].

GLAGOV (N=968), published in JAMA in 2016, showed that evolocumab versus placebo produced 0.95% greater regression in percent atheroma volume by intravascular ultrasound over 76 weeks, with 64.3% of evolocumab patients achieving plaque regression versus 47.3% on placebo (P<0.001) [14].

The HAUSER-RCT (N=300), published in the New England Journal of Medicine Evidence in 2022, evaluated monthly subcutaneous evolocumab in patients with HoFH not on apheresis, showing a 26.4% reduction in LDL-C from baseline versus placebo over 24 weeks [15].

For familial hypercholesterolemia specifically, the European Atherosclerosis Society consensus statement (2021) recommends PCSK9 inhibitor therapy for HeFH patients who fail to achieve LDL-C targets on maximum-dose statin plus ezetimibe [16]. The American Heart Association and American College of Cardiology 2022 expert consensus decision pathway on non-statin therapies states: "For patients with clinical ASCVD at very high risk who require additional LDL-C lowering, a PCSK9 inhibitor is recommended if the LDL-C remains 70 mg/dL or higher on maximally tolerated statin and ezetimibe therapy" [2].

ODYSSEY OUTCOMES (N=18,924), the comparable outcomes trial for alirocumab (Praluent), showed a 15% relative risk reduction in the primary MACE endpoint, providing additional class-level evidence for PCSK9 inhibitor benefit and supporting insurer coverage decisions for evolocumab by analogy [17].

Adverse event rates in FOURIER were low. Injection-site reactions occurred in 2.1% of evolocumab-treated patients versus 1.6% on placebo. Neurocognitive adverse events, which were a theoretical concern in early PCSK9 inhibitor trials, were not significantly different between arms (1.6% vs. 1.5%) over the study period [3].

Telehealth Prescribing of Repatha in Washington

Washington state permits telehealth prescribing of Schedule-exempt prescription medications, including PCSK9 inhibitors, by licensed prescribers practicing within the state. The Washington Telehealth Act (RCW 74.09.325) and subsequent Department of Health guidance established synchronous and asynchronous telehealth as valid modes of clinical evaluation for new prescriptions, provided a prescriber-patient relationship is established [18].

HealthRX prescribers licensed in Washington can evaluate cardiovascular risk, review prior lipid panels, and initiate or continue Repatha prescriptions via telehealth visit. Prescriptions are transmitted electronically to the patient's pharmacy of choice or to a partnered 503A compounding pharmacy for cost-minimizing access.

The Washington State Medical Association guidance on telehealth prescribing requires that the prescriber document a clinical evaluation sufficient to establish a diagnosis and that controlled-substance-specific restrictions (not applicable to Repatha) are observed. For PCSK9 inhibitor initiations, a recent lipid panel (within 12 months) and documentation of statin therapy history are sufficient for the prescriber to establish clinical need [18].

A 2022 study in the Journal of the American Heart Association (N=4,210) found that telehealth-initiated statin and non-statin lipid therapy achieved equivalent LDL-C reduction at 12 months compared with in-person initiation (mean LDL-C reduction 41.2 mg/dL vs. 40.8 mg/dL, P=0.74), supporting the clinical validity of telehealth-based lipid management [19].

Prior Authorization Strategy for Washington Patients

Prior authorization for Repatha is the single most time-consuming barrier for Washington patients. A structured submission reduces denial rates. The following documentation supports most commercial and Medicaid PA submissions in Washington:

LDL-C documentation. Provide two fasting LDL-C values above the plan's threshold, typically 70 mg/dL for ASCVD patients and 100 mg/dL for primary prevention high-risk patients, drawn at least 4 weeks apart on stable statin therapy.

Statin history. List each statin tried, the dose, the duration, and the reason for discontinuation or dose limitation. Muscle toxicity should be supported by CK levels or clinical notes; hepatic intolerance should reference LFT values.

Ezetimibe trial. Most Washington commercial plans require documented ezetimibe 10 mg daily for at least 4 to 12 weeks. Record the LDL-C on combination therapy.

Indication documentation. For ASCVD, include ICD-10 codes (I25.10 for coronary artery disease, I69.350 for post-MI, I63.9 for ischemic stroke, etc.). For HeFH, include genetic testing results or a Dutch Lipid Clinic Network score of 6 or above.

The ACC's 2023 PA toolkit for lipid-lowering therapies, available through ACC.org, provides template language that many Washington plans accept [2]. Peer-to-peer review with the plan's medical director, requested within 72 hours of an initial denial, overturns approximately 28% to 45% of PCSK9 inhibitor PA denials in commercial markets based on 2022 specialty pharmacy data [8].

Dosing and Administration in Washington Clinical Practice

Repatha is approved at two dosing regimens for LDL-C reduction: 140 mg subcutaneously every two weeks or 420 mg subcutaneously once monthly. For HoFH, dosing is 420 mg once monthly; if LDL-C response is inadequate after 12 weeks, some clinicians increase to 420 mg every two weeks in consultation with a lipidologist [1].

The 420 mg monthly dose uses three consecutive 140 mg injections given within 30 minutes (using the SureClick auto-injector) or a single 3.5 mL prefilled cartridge with the Pushtronex on-body infusor, which delivers the dose over 5 to 9 minutes. Patient training on injection technique is available through Amgen's nurse educator program and through HealthRX's onboarding protocol [1].

Refrigerated storage at 36 to 46 degrees Fahrenheit is required. Patients may store the device at room temperature (up to 77 degrees Fahrenheit) for a single 30-day period. Freezing renders the product unusable [1].

LDL-C response is typically measurable within 4 weeks of the first injection. The ACC/AHA 2019 guideline recommends confirming LDL-C response at 4 to 12 weeks after initiation and every 3 to 12 months thereafter to assess adherence and therapeutic effect [6].